Hello, Im still here Just don't have much to say.
We need Time Time Time - Silly to think short term here
just read the articles, its all in the future. GTCB would
only go up here on real eminent news. We need to wait
then wait then wait again. However the rewards will be
there, but only if you can WAIT. From this article tell
me something that would push this stock before the first
quarter of '08 or last quarter for that mater!
Our European partner for ATryn®, LEO Pharma A/S, has made good progress in the quarter in introducing the product to the physician community in Europe for the hereditary deficiency indication while also initiating the Phase II clinical study for the large market indication in disseminated intravascular coagulation, or DIC, associated with severe sepsis," stated Geoffrey F. Cox, Ph.D., GTC's Chairman of the Board and Chief Executive Officer. "We are also making strong progress in developing our follow-on biologic strategy. We have added a CD20 monoclonal antibody program to the recombinant factor VIIa program in our partnership with LFB Biotechnologies. Both of these programs may be eligible for development as follow-on biologics once appropriate legislation is enacted and regulatory guidance is established in the US and EU."
ATryn® Commercial Launch Activities and Clinical Progress
LEO Pharma initiated the launch of ATryn® at the International Society on Thrombosis and Haemostasis Congress held in Geneva in July. This introduction included a symposium, poster presentations, an exhibit booth and press conferences. LEO is in the process of establishing prices in various European countries. The first commercial sales are anticipated to be in the United Kingdom and will occur in additional countries as pricing is established.
LEO has opened clinical sites and initiated patient enrollment for the Phase II dose ranging study in approximately 200 DIC patients. DIC is the widespread formation of clots within blood vessels, which often leads to organ failure, and is often associated with severe sepsis. In this indication, the infection and resulting septic condition consume much of the patient's own antithrombin. This antithrombin deficiency then results in DIC. In addition to a number of research studies that support the potential therapeutic value of antithrombin for this indication, DIC is an approved indication for plasma-derived antithrombin in Japan. DIC occurs in an estimated 500,000 severe sepsis cases in the US and European Union each year, of which up to 50% are fatal, representing a major unmet medical need of significant interest in critical care. We estimate the market size of the DIC indication in the US is $2 billion to 3 billion with additional similarly sized markets in Europe and Japan.
AI
